UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies

Frontiers in pharmacology, 2021-09, Vol.12, p.729249-729249

Sharif, Najam A.

2021

Volltextzugriff (PDF)

Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients

Pharmaceuticals (Basel, Switzerland), 2023-05, Vol.16 (6), p.791

Sharif, Najam A

2023

Volltextzugriff (PDF)

Elevated Intraocular Pressure and Glaucomatous Optic Neuropathy: Genes to Disease Mechanisms, Therapeutic Drugs, and Gene Therapies

Pharmaceuticals (Basel, Switzerland), 2023-06, Vol.16 (6), p.870

Sharif, Najam A

2023

Volltextzugriff (PDF)

Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma

British journal of pharmacology, 2019-04, Vol.176 (8), p.1051-1058

2019

Volltextzugriff (PDF)

Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility

British journal of pharmacology, 2019-04, Vol.176 (8), p.1059-1078

2019

Volltextzugriff (PDF)

Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision

Neural regeneration research, 2018-07, Vol.13 (7), p.1145-1150

Sharif, Najam

2018

Volltextzugriff (PDF)

Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation

Current research in neurobiology, 2022-01, Vol.3, p.100037-100037, Article 100037

Sharif, Najam A.

2022

Volltextzugriff (PDF)

Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

International journal of molecular sciences, 2024-03, Vol.25 (6), p.3328

2024

Volltextzugriff (PDF)

Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future

Frontiers in neurology, 2022-08, Vol.13, p.964197

2022

Volltextzugriff (PDF)

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Pharmaceuticals (Basel, Switzerland), 2024-06, Vol.17 (6), p.798

2024

Volltextzugriff (PDF)

Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug

Current opinion in pharmacology, 2024-02, Vol.74, p.102426-102426, Article 102426

Sharif, Najam A.

2024

Volltextzugriff (PDF)

Gene therapies and gene product-based drug candidates for normalizing and preserving tissue functions in animal models of ocular hypertension and glaucoma

Molecular aspects of medicine, 2023-12, Vol.94, p.101218-101218, Article 101218

Sharif, Najam A.

2023

Volltextzugriff (PDF)

Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness

Experimental eye research, 2023-07, Vol.232, p.109444-109444, Article 109444

Sharif, Najam A.

2023

Volltextzugriff (PDF)

MicroRNA profile of extracellular vesicles released by Müller glial cells

Frontiers in cellular neuroscience, 2024-01, Vol.17, p.1325114-1325114

2024

Volltextzugriff (PDF)

The Role of Autophagy in Chemical Proteasome Inhibition Model of Retinal Degeneration

International journal of molecular sciences, 2021-07, Vol.22 (14), p.7271

2021

Volltextzugriff (PDF)

PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects

BioFactors (Oxford), 2022-11, Vol.48 (6), p.1226-1249

Sharif, Najam A.

2022

Volltextzugriff (PDF)

FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma

Experimental eye research, 2023-04, Vol.229, p.109415-109415, Article 109415

2023

Volltextzugriff (PDF)

Synthetic FP-prostaglandin-induced contraction of rat uterus smooth muscle in vitro

Prostaglandins, leukotrienes and essential fatty acids, 2008-03, Vol.78 (3), p.199-207

Sharif, Najam A

2008

Volltextzugriff (PDF)

Safety of intravitreally delivered AAV2 vector‐mediated multi‐characteristic opsin genetic construct in wild type beagle dogs

The journal of gene medicine, 2024-07, Vol.26 (7), p.e3720-n/a

2024

Volltextzugriff (PDF)

Rapid Identification of Novel Inhibitors of the Human Aquaporin-1 Water Channel

Chemical biology & drug design, 2016-05, Vol.87 (5), p.794-805

2016

Volltextzugriff (PDF)

Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors

Neural regeneration research, 2023-01, Vol.18 (1), p.5-17

Sharif, Najam

2023

Volltextzugriff (PDF)

Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810

ACS pharmacology & translational science, 2020-12, Vol.3 (6), p.1391-1421

Sharif, Najam A

2020

Volltextzugriff (PDF)

Pharmacological evidence for a functional serotonin-2B receptor in a human uterine smooth muscle cell line

The Journal of pharmacology and experimental therapeutics, 2006-06, Vol.317 (3), p.1254

2006

Volltextzugriff (PDF)

Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes

Journal of ocular pharmacology and therapeutics, 2015-04, Vol.31 (3), p.131

Sharif, Najam A

2015

Volltextzugriff (PDF)

Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling

Investigative ophthalmology & visual science, 2010-11, Vol.51 (11), p.5817-5824

2010

Volltextzugriff (PDF)

1 – 25 von 154

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(111)

Publikationsform

Sprache

Englisch
(154)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies

Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients

Elevated Intraocular Pressure and Glaucomatous Optic Neuropathy: Genes to Disease Mechanisms, Therapeutic Drugs, and Gene Therapies

Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma

Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility

Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision

Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation

Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug

Gene therapies and gene product-based drug candidates for normalizing and preserving tissue functions in animal models of ocular hypertension and glaucoma

Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness

MicroRNA profile of extracellular vesicles released by Müller glial cells

The Role of Autophagy in Chemical Proteasome Inhibition Model of Retinal Degeneration

PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects

FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma

Synthetic FP-prostaglandin-induced contraction of rat uterus smooth muscle in vitro

Safety of intravitreally delivered AAV2 vector‐mediated multi‐characteristic opsin genetic construct in wild type beagle dogs

Rapid Identification of Novel Inhibitors of the Human Aquaporin-1 Water Channel

Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors

Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810

Pharmacological evidence for a functional serotonin-2B receptor in a human uterine smooth muscle cell line

Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes

Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling

Suchergebnisse filtern